Fanconi anemia (FA) is a disease resulting from autosomal recessive defects in any of at least eight genes, indicating a complex interaction or pathways. The disease is characterized by marrow by marrow failure. The disease is characterized by marrow failure, chromosome instability, increased incidence of leukemia and developmental defects. Cells from patients with FA are hypersensitive to DNA crosslinking agents, so the role of the FA proteins in crosslink repair is an important question. Project 1 will study the molecular action of the FA genes and the relation of crosslink repair to the pathogenesis of the disease. There are three goals. (1) Our PPG group has narrowed the search for the FANCD gene to a small region of chromosome 3p26. Isolation and characterization of this gene and its product will be primary near term goal for this project with Project 2. (2) After isolation of the FANCD gene, definition of the action of the FANCD protein and its possible role in crosslink repair will be the goal . FANCD protein localization and interactions will be tested. Proteins which interact with FANCD will be evaluated as candidates for """"""""new"""""""" FA gene products. (3) As a third objective, an alternative approach to understanding A will be taken. Mouse mutants in two genes which are crosslink repair-specific, SNMl and REV3 will be constructed, in order to determine phenotypic similarities to FA and to test the hypothesis that DNA crosslink repair defects are causative in the pathogenesis of FA.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL048546-09
Application #
6608272
Study Section
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
$124,146
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Whiteaker, Jeffrey R; Zhao, Lei; Ivey, Richard G et al. (2018) Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. DNA Repair (Amst) 65:47-53
Mouw, Kent W; Goldberg, Michael S; Konstantinopoulos, Panagiotis A et al. (2017) DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 7:675-693
Kroeger Jr, Paul T; Drummond, Bridgette E; Miceli, Rachel et al. (2017) The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development. Dev Biol 428:148-163
Rondinelli, Beatrice; Gogola, Ewa; YĆ¼cel, Hatice et al. (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19:1371-1378
Karras, Georgios I; Yi, Song; Sahni, Nidhi et al. (2017) HSP90 Shapes the Consequences of Human Genetic Variation. Cell 168:856-866.e12
Garbati, Michael R; Hays, Laura E; Rathbun, R Keaney et al. (2016) Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages. J Leukoc Biol 99:455-65
Zhang, Qing-Shuo; Tang, Weiliang; Deater, Matthew et al. (2016) Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood 128:2774-2784
Zhang, Haojian; Kozono, David E; O'Connor, Kevin W et al. (2016) TGF-? Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell 18:668-81
Zhang, Qing-Shuo; Benedetti, Eric; Deater, Matthew et al. (2015) Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. Stem Cell Reports 4:90-102
Lombardi, Anne J; Hoskins, Elizabeth E; Foglesong, Grant D et al. (2015) Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res 21:1962-72

Showing the most recent 10 out of 106 publications